Drug Profile

BMS 911543

Alternative Names: BMS-911543

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bristol-Myers Squibb
Class Antineoplastics; Small molecules
Mechanism of Action Janus kinase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Myelofibrosis

Most Recent Events

09 Oct 2017 Discontinued - Phase-I/II for Myelofibrosis in Australia and USA (PO) (Drug not listed on Bristol-Myers Squibb pipeline, October 2017)
16 Sep 2015 Bristol-Myers Squibb completes enrolment in its phase I/II trial for Myelofibrosis in USA and Australia (NCT01236352)
06 Jun 2011 Phase-I/II clinical trials in Myelofibrosis in Australia (PO) (NCT01236352)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com